Fred Hutchinson
Fred Hutchinson Cancer Research Center names new president, director
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
Harnessing the gut to improve cancer outcomes
Melanoma rates decline among US adolescents, young adults
Off-the-shelf natural killer cells safe, clinically active for advanced Merkel cell carcinoma
Hematologists, oncologists elected to National Academy of Medicine
NCI-sponsored clinical trials cost-effective, ‘practice influential’
T-cell Responses to Concurrent HIV and Herpesvirus Infections
An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.
TCR-engineered T Cells in Solid Tumors (ACTengine)
NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.